Treatment of inflammatory myopathies

被引:0
作者
Mastaglia, FL
Phillips, BA
Zilko, P
机构
[1] QUEEN ELIZABETH II MED CTR,DEPT MED,PERTH,WA 6009,AUSTRALIA
[2] QUEEN ELIZABETH II MED CTR,DEPT NEUROL,PERTH,WA 6009,AUSTRALIA
[3] QUEEN ELIZABETH II MED CTR,DEPT CLIN IMMUNOL,PERTH,WA 6009,AUSTRALIA
关键词
inflammatory myopathies; treatment; polymyositis; dermatomyositis; inclusion body myositis;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The treatment of the immune-mediated inflammatory myopathies remains largely empirical. Corticosteroids are usually effective in polymyositis and dermatomyositis but may need to be combined with methotrexate or azathioprine in some patients, Intravenous immunoglobulin (IVIg) is effective as add-on therapy in some patients not adequately controlled with steroids or immunosuppressive agents, but further controlled trials of IVIg are necessary to define the indications and optimal dose regimens. Cyclophosphamide, cyclosporin, or chlorambucil may be effective in patients with refractory polymyositis or dermatomyositis. Low-dose whole body or lymphoid irradiation is a last option in severely disabled patients resistant to all other treatments. As a small proportion of patients with inclusion body myositis respond to corticosteroid or immunosuppressive therapy, a 3-6-month trial of such therapy is justified in this condition. More specific immunotherapy for these disorders awaits identification of the target antigens and further clarification of the immunopathogenetic mechanisms. (C) 1997 John Wiley & Sons, Inc.
引用
收藏
页码:651 / 664
页数:14
相关论文
共 50 条
  • [41] Idiopathic inflammatory myopathies: one year in review 2022
    Dourado, E.
    Bottazzi, F.
    Cardelli, C.
    Conticini, E.
    Schmidt, J.
    Cavagna, L.
    Barsotti, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 199 - 213
  • [42] Idiopathic inflammatory myopathies - myositis
    Dorph, C
    Lundberg, IE
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2002, 16 (05): : 817 - 832
  • [43] Juvenile Dermatomyositis and the Inflammatory Myopathies
    Swafford, Collin
    Roach, E. Steve
    SEMINARS IN NEUROLOGY, 2020, 40 (03) : 342 - 348
  • [44] Inflammatory myopathies: disease mechanisms
    Greenberg, Steven A.
    CURRENT OPINION IN NEUROLOGY, 2009, 22 (05) : 516 - 523
  • [45] Use of methotrexate in inflammatory myopathies
    Fendler, C.
    Braun, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (05) : S164 - S167
  • [46] One year in review 2016: idiopathic inflammatory myopathies
    Orlandi, M.
    Barsotti, S.
    Cioffi, E.
    Tenti, S.
    Toscano, C.
    Baldini, C.
    Neri, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : 966 - 974
  • [47] Inflammatory myopathies: Evaluation and management
    Greenberg, Steven A.
    SEMINARS IN NEUROLOGY, 2008, 28 (02) : 241 - 249
  • [48] Inflammatory myopathies: an update for neurologists
    Serafim Silva, Andre Macedo
    Campos, Eliene Dutra
    Zanoteli, Edmar
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2022, 80 (05) : 238 - 248
  • [49] History of Idiopathic Inflammatory Myopathies
    Reimers, Carl D.
    AKTUELLE RHEUMATOLOGIE, 2022, 47 (05) : 424 - 431
  • [50] Idiopathic inflammatory myopathies: one year in review 2021
    Cardelli, C.
    Zanframundo, G.
    Cometi, L.
    Marcucci, E.
    Biglia, A.
    Cavagna, L.
    Barsotti, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (02) : 199 - 209